New pill tested to fight tough bile duct cancer
NCT ID NCT06420349
Summary
This early-stage study aimed to find a safe dose and test the initial effects of a new oral drug called NXP800 for patients with advanced bile duct cancer (cholangiocarcinoma) that had spread or stopped responding to standard treatments. The drug works by blocking a specific pathway in cancer cells that helps them grow and spread. The trial was small and terminated early, focusing primarily on safety and determining the right dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.